Literature DB >> 25237574

MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis.

Abbas Ebrahimi Kalan1, Jafar Soleimani Rad2, Laya Kafami3, Daryoush Mohamadnezhad2, Amir Afshin Khaki2, Amaneh Mohammadi Roushandeh4.   

Abstract

BACKGROUND: Cytokines are secreted signaling proteins which play essential roles in immune responses during experimental autoimmune encephalomyelitis (EAE), a demyelinating model that mimics many features of multiple sclerosis (MS). Interleukin 6 (IL-6) is a multifunctional cytokine produced by different cells, mediating inflammatory reactions and immune-mediated processes. Several studies have described immunosuppressive potentials of several herbal medicines. MS14 as an Iranian marine herbal medicine has anti-inflammatory and immunomodulatory activities.
OBJECTIVES: The present study investigated the immunosuppressive potential of MS14 as an herbal drug as well as the IL-6 level in EAE model. We hope it will be a new approach for neurologic diseases and autoimmune originated diseases therapy. PATIENTS AND METHODS: The present experimental study was a collaboration between Department of Anatomical Sciences of Tabriz University of Medical Sciences and Shefa Neuroscience Research Center of Tehran. We used 30 C57BL/6 mice. The animals were immunized with myelin oligodendrocyte glycoprotein (MOG) to induce EAE and treated with MS14-containing (30%) diets. Subjects were selected by simple random sampling and then they were randomly allocated to two groups. EAE symptoms were assessed using the standard 10-point EAE scoring system from the seventh to the 35th day after immunization. Afterwards, the spleen was removed and its cells were cultured with or without MOG 35-55; then, the IL-6 level was analyzed by ELISA. In addition, histopathological studies were carried out for demyelination lesion evaluation in the spinal cord.
RESULTS: MS14 significantly improved clinical symptoms of EAE compared with the control (P < 0.05). It also suppressed proliferative responses of T cells and decreased IL-6 expression (16.93 ± 2.7 vs. 21.4 ± 3.33) (P < 0.05).
CONCLUSIONS: Our results strongly suggested that IL-6 as a potential molecule could have a role in neuroimmunology and neuroinflammation, which is in congruent with previous studies. Therefore, it can be a clear target in strategic therapies and support effective properties of phytotherapy in EAE and MS treatment.

Entities:  

Keywords:  EAE; Herbal Medicine; Interleukin-6

Year:  2014        PMID: 25237574      PMCID: PMC4166093          DOI: 10.5812/ircmj.16956

Source DB:  PubMed          Journal:  Iran Red Crescent Med J        ISSN: 2074-1804            Impact factor:   0.611


  29 in total

1.  The effect of MS14 on innate and cellular immune responses in BALB/c mice.

Authors:  Roya Yaraee; Tooba Ghazanfari; Marzieh Eghtedardoost; Masoumeh Rajabi; Mohsen Naseri
Journal:  Immunopharmacol Immunotoxicol       Date:  2011-02-02       Impact factor: 2.730

2.  Interleukin-6 expression in human multiple sclerosis lesions.

Authors:  L M Schönrock; G Gawlowski; W Brück
Journal:  Neurosci Lett       Date:  2000-11-10       Impact factor: 3.046

3.  Serum level of interleukin-6 in Chinese patients with multiple sclerosis.

Authors:  Ying-Chun Chen; Xin Yang; Ling Miao; Zhen-Guo Liu; Wei Li; Zhong-Xin Zhao; Xiao-Jiang Sun; Guo-Xin Jiang; Sheng-Di Chen; Qi Cheng
Journal:  J Neuroimmunol       Date:  2012-05-25       Impact factor: 3.478

4.  Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.

Authors:  A Karczewska; S Nawrocki; D Breborowicz; V Filas; A Mackiewicz
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

5.  Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.

Authors:  Orhan Aktas; Timour Prozorovski; Alina Smorodchenko; Nicolai E Savaskan; Roland Lauster; Peter-Michael Kloetzel; Carmen Infante-Duarte; Stefan Brocke; Frauke Zipp
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

6.  Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation.

Authors:  Wei Wei; Changsheng Du; Jie Lv; Guixian Zhao; Zhenxin Li; Zhiying Wu; György Haskó; Xin Xie
Journal:  J Immunol       Date:  2012-12-05       Impact factor: 5.422

7.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

8.  Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12.

Authors:  Burkhard Becher; Brigit G Durell; Randolph J Noelle
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 9.  The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation.

Authors:  Alla L Zozulya; Heinz Wiendl
Journal:  Hum Immunol       Date:  2008-08-22       Impact factor: 2.850

10.  Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study.

Authors:  Masoud Etemadifar; Farnaz Sayahi; Seyed-Hossein Abtahi; Hamidreza Shemshaki; Gholam-Ali Dorooshi; Mohammad Goodarzi; Mojtaba Akbari; Mahboobeh Fereidan-Esfahani
Journal:  Int J Neurosci       Date:  2013-02-11       Impact factor: 2.292

View more
  1 in total

1.  A Novel Combination of Docosahexaenoic Acid, All-Trans Retinoic Acid, and 1, 25-Dihydroxyvitamin D3 Reduces T-Bet Gene Expression, Serum Interferon Gamma, and Clinical Scores but Promotes PPARγ Gene Expression in Experimental Autoimmune Encephalomyelitis.

Authors:  Mohammad Reza Shiri-Shahsavar; Abbas Mirshafiee; Karim Parastouei; Abbas Ebrahimi-Kalan; Saeed Yekaninejad; Farid Soleymani; Reza Chahardoli; Ramin Mazaheri Nezhad Fard; Ali Akbar Saboor-Yaraghi
Journal:  J Mol Neurosci       Date:  2016-09-19       Impact factor: 3.444

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.